[1]沈有录,卢红涛,刘维军.阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响[J].医学信息,2019,32(06):67-71.[doi:10.3969/j.issn.1006-1959.2019.06.022]
　SHEN You-lu,LU Hong-tao,LIU Wei-jun.Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI[J].Journal of Medical Information,2019,32(06):67-71.[doi:10.3969/j.issn.1006-1959.2019.06.022]
点击复制

阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年06期
页码:
67-71
栏目:
论著
出版日期:
2019-03-15

文章信息/Info

Title:
Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI
文章编号:
1006-1959（2019）06-0067-05
作者:
沈有录1; 卢红涛2; 刘维军1
（1.青海大学附属医院心血管内科，青海 西宁 810001；2.湖北省荆州市中心医院心血管内科，湖北 荆州 434020）
Author(s):
SHEN You-lu1; LU Hong-tao2; LIU Wei-jun1
(1.Department of Cardiology,Affiliated Hospital of Qinghai University,Xining 810001,Qinghai,China;2.Department of Cardiology,Jingzhou Central Hospital,Jingzhou 434020,Hubei,China)
关键词:
瑞舒伐他汀; 阿托伐他汀; 高海拔; PCI; 血脂; 炎症因子; 血管内皮功能
Keywords:
Rosuvastatin; Atorvastatin; High altitude; PCI; Lipid; Inflammatory factors; Vascular endothelial function
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2019.06.022
文献标志码:
A
摘要:
目的 探讨阿托伐他汀和瑞舒伐他汀对高海拔地区经皮冠状动脉介入治疗（PCI）后患者血脂、炎症因子和血管内皮功能的影响。方法 选自青海大学附属医院心内科2015年4月~2016年4月的行PCI术的冠心病患者64例为研究对象。在给予相同基础药物治疗前提下，随机分组为阿托伐他汀组和瑞舒伐他汀组，每组32例。分别监测两组PCI前、PCI后3个月、PCI后6个月时间点总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、超敏C反应蛋白（Hs-CRP）、同型半胱氨酸（Hcy）、颈动脉内膜中层厚度（IMT）、肱动脉血流介导的血管内皮舒张功能（FMD），分别比较两组在PCI前和PCI后3个月、6个月时TC、TG、HDL、LDL、Hs-CRP、Hcy、IMT、FMD的变化。结果 两组PCI前的TC、TG、HDL、LDL、Hs-CRP、Hcy、IMT、FMD比较，差异无统计学意义（P＞0.05）。两组PCI后3个月、6个月时TC、TG、LDL、Hs-CRP、Hcy、IMT均较PCI前下降，且PCI后6个月较PCI后3个月下降更显著，瑞舒伐他汀组较阿托伐他汀组下降明显，差异有统计学意义（P＜0.05）。两组PCI后3个月、6个月时HDL、FMD均较PCI前升高，且PCI后6个月较PCI后3月升高更显著，瑞舒伐他汀组较阿托伐他汀组升高明显，差异有统计学意义（P＜0.05）。结论 阿托伐他汀和瑞舒伐他汀对高海拔地区PCI后患者的血脂有调节作用，还有抑制机体炎症反应和改善血管内皮功能的作用。瑞舒伐他汀比阿托伐他汀的效果更显著。
Abstract:
Objective To investigate the effects of atorvastatin and rosuvastatin on serum lipids, inflammatory factors and vascular endothelial function in patients undergoing percutaneous coronary intervention (PCI) at high altitude. Methods A total of 64 patients with coronary heart disease who underwent PCI from April 2015 to April 2016 in Qinghai University Affiliated Hospital were included in the study. Under the premise of the same basic drug treatment, the patients were randomly divided into atorvastatin group and rosuvastatin group, 32 cases in each group.Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), super-group were monitored before PCI, 3 months after PCI, and 6 months after PCI. Sensitive C-reactive protein (Hs-CRP), homocysteine (Hcy), carotid intima-media thickness (IMT), and brachial artery blood flow-mediated vascular endothelial dilation function (FMD) were compared between the two groups in PCI. Changes in TC, TG, HDL, LDL, Hs-CRP, Hcy, IMT, and FMD at 3 months and 6 months after PCI. Results There were no significant differences in TC, TG, HDL, LDL, Hs-CRP, Hcy, IMT and FMD between the two groups before PCI (P>0.05).At 3 months and 6 months after PCI, TC, TG, LDL, Hs-CRP, Hcy and IMT were lower than those before PCI, and 6 months after PCI was more significant than 3 months after PCI. The statin group was significantly lower than the atorvastatin group,the difference was statistically significant (P<0.05). At 3 months and 6 months after PCI, HDL and FMD were higher than those before PCI, and 6 months after PCI was more significant than that after PCI. The rosuvastatin group was higher than the atorvastatin group,the difference was statistically significant (P<0.05). Conclusion Atorvastatin and rosuvastatin have a regulatory effect on blood lipids in patients with high altitude PCI, as well as inhibition of inflammatory response and improvement of vascular endothelial function. Rosuvastatin is more effective than atorvastatin.

参考文献/References:

[1]闻松男,杜昕,马长生.冠状动脉介入患者他汀降脂治疗的研究进展[J].心肺血管病杂志,2013,32(2):230-232. [2]F.De Meester,R.R.Watson.Handbook of Lipids in Human Function[M].Elsevier Inc,2016:319-329. [3]高远,关启刚,孙宇姣,等.急性冠脉综合征患者应用负荷剂量的瑞舒伐他汀与阿托伐汀的效果对比[J].中国医科大学学报,2013,42(3):235-239. [4]Briguori C,Madonna R,Zimarino M,et al.Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty-the Remedy Trial[J].Cardiovascular Drugs and Therapy,2016,30(5):465-472. [5]Echeverri D,Cabrales J.Statins and percutaneous coronary intervention:A complementary synergy[J].Clin Investig Arterioscler,2013,25(3):112-122. [6]Monguchi T,Hara T,Hasokawa M,et al.Excessive intake of trans fatty acid accelerates atherosclerosis through promoting inflammation and oxidative stress in a mouse model of hyperlipidemia[J].Journal of Cardiology,2017,70(2):121-127. [7]王正东,李平,林智海,等.血管损伤及PCI术后再狭窄机制的研究进展和相应对策[J].医学综述,2016,22(2):280-283. [8]杨铠榕,周静,刘卫生.冠状动脉粥样硬化性心脏病药物支架植入术后支架内再狭窄影响因素分析[J].岭南心血管病杂志,2017,23(4):488-490. [9]贾慧宇,程光慧.负量加高维持量阿托伐他汀对ACS行PCI患者炎症因子及血管内皮功能的影响[J].河北医科大学学报,2018,39(10):1131-1134. [10]熊小栓,曾繁芳,陈娟.阿托伐他汀序贯疗法对择期PCI治疗患者降脂和抗炎作用的疗效[J].心血管康复医学杂志,2018,27(4):440-443. [11]Attalla DM,Ahmed LA,Zaki HF,et al.Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation[J].Biomedicine & Pharmacotherapy,2018,104(5):542-549. [12]Ansari R,Mahta A,Mallack E,et al.Hyperhomocysteinemia and neurologic disorders: a review[J].J Clin Neurol,2014,10(4):281-288. [13]周昌钻,潘孙雷,林辉,等.瑞舒伐他汀对同型半胱氨酸诱导的小鼠血管平滑肌细胞去分化和内质网应激的影响及其机制研究[J].中国应用生理学杂志,2018,34(1):43-47. [14]易梦阳,谭俊晖,张爱爱,等.同型半胱氨酸与动脉粥样硬化机制的研究进展[J].河北北方学院学报（自然科学版）,2018,34(10):56-60. [15]晏彪,张思思,邓媛.血浆致动脉硬化指数联合颈动脉内膜中层厚度在冠心病患者风险评估中的应用[J].心脑血管病防治,2018,18(2):121-122. [16]Conde L,Bevan S,Sitzer M,et al.Novel Associations forcoronary artery disease derived from genome wide association studies are not associated with increased carotid intimamedia thickness，suggesting they do not act via early atherosclerosis or vessel remodeling[J].Atherosclerosis,2011,219(2):684-689. [17]齐杰.颈动脉内中膜厚度与血管炎性因子的相关性分析[J].中国药物与临床,2017,17(12):1811-1812. [18]中国医师协会内分泌代谢科医师分会.2型糖尿病早期大血管病变无创性检查的专家共识[J].中国循环杂志,2014,29(3):167-171. [19]刘欢,刘润冬,王宏宇.血管内皮功能的评价及其临床价值[J].心血管病学进展,2016,37(4):426-429. [20]黄澄,李霞.基于肱动脉血流阻断的血管功能检测及临床应用[J].北京生物医学工程,2016,35(4):435-438.

相似文献/References:

[1]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(06):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[2]王润俊.阿托伐他汀改善蛛网膜下腔出血患者的预后分析[J].医学信息,2018,31(14):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
　WANG Run-jun.Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage[J].Journal of Medical Information,2018,31(06):142.[doi:10.3969/j.issn.1006-1959.2018.14.043]
[3]袁 敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对 血小板参数的影响[J].医学信息,2018,31(16):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
　YUAN Min,ZHOU Yuan-cheng.Effect of Atorvastatin Combined with Antiplatelet Drugs on Patients with Cerebral Thrombosis and its Influence on Platelet Parameters[J].Journal of Medical Information,2018,31(06):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
[4]赵殿儒,祁景蕊.不同剂量瑞舒伐他汀对急性冠脉综合征患者心功能和炎症因子的影响[J].医学信息,2019,32(01):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
　ZHAO Dian-ru,YAN Jing-rui.Effects of Different Doses of Rosuvastatin on Cardiac Function and Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Journal of Medical Information,2019,32(06):148.[doi:10.3969/j.issn.1006-1959.2019.01.046]
[5]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Journal of Medical Information,2019,32(06):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[6]沈有录,刘维军,吴青霞,等.瑞舒伐他汀对置入冠状动脉支架患者的近期疗效[J].医学信息,2019,32(09):144.[doi:10.3969/j.issn.1006-1959.2019.09.047]
　SHEN You-lu,LIU Wei-jun,WU Qing-xia,et al.Short-term Efficacy of Rosuvastatin in Patients with Coronary Stents[J].Journal of Medical Information,2019,32(06):144.[doi:10.3969/j.issn.1006-1959.2019.09.047]
[7]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Journal of Medical Information,2019,32(06):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[8]高占群,李 霜,刘 杨.立普妥与瑞舒伐他汀联合缬沙坦治疗糖尿病 并发心力衰竭的临床疗效[J].医学信息,2019,32(15):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Efficacy of Lipitor and Rosuvastatin Combined with Valsartan in the Treatment of Diabetes Complicated with Heart Failure[J].Journal of Medical Information,2019,32(06):140.[doi:10.3969/j.issn.1006-1959.2019.15.045]
[9]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(06):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[10]安志卫,刘 娜,薛芳芳.阿托伐他汀联合硫酸氢氯吡格雷治疗脑血栓的效果观察[J].医学信息,2019,32(17):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
　AN Zhi-wei,LIU Na,XUE Fang-fang.Effect of Atorvastatin Combined with Clopidogrel Hydrogen Sulfate on Cerebral Thrombosis[J].Journal of Medical Information,2019,32(06):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
[11]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Journal of Medical Information,2022,35(06):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]

更新日期/Last Update: 2019-03-15